Home » Newsletters » BioWorld Science

BioWorld Science

March 31, 2020

View Archived Issues

Butyrate affects regulatory B cells, rheumatoid arthritis

Lamin A/C's presence in nucleus, absence from membrane both problematic in progeria

New animal model more accurate for assessing nerve agent poisoning countermeasures

Screening opens in U.K. for first-in-human study of COVID-19 vaccine candidate ChAdOx1 nCoV-19

FDA approves Taltz for pediatric patients with plaque psoriasis

SMOC1 as a novel therapeutic target in atopic dermatitis

ISA-101 vaccine demonstrates promising efficacy in advanced cervical cancer

New serine-protein kinase ATM inhibitors disclosed by Suzhou Zanrong Pharma

Jiangsu Chia Tai Tianqing Pharmaceutical Group patents BTK inhibitors

Chengdu Origin Biotechnology discovers proteosome inhibitors

New melanocortin MC4 receptor agonists synthesized at Novo Nordisk

Roche identifies new HBV cccDNA inhibitors

Structural studies show similarities and differences in SARS, COVID-19 receptor binding

New Parkinson's disease model induced via dysregulation in dopamine sequestration

Researchers identify biomarkers for monitoring progression of colorectal cancer

HMPL-453 begins new phase II study in China for advanced malignant mesothelioma

Inovio reports phase II interim data on VGX-3100 in HPV-related vulvar dysplasia

Golden Biotech advances phase I/II study of antroquinonol for stage IV metastatic pancreatic cancer

Interim phase I data show confirmed responses with XMT-1536 in pretreated ovarian cancer and NSCLC

DNASE1L3 is a diagnostic marker of ankylosing spondylitis

European Commission approves Nubeqa for nonmetastatic castration-resistant prostate cancer

Otsuka studies OPC-214870 in subjects with history of photoparoxysmal response on EEG

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...